Inavolisib plus letrozole or fulvestrant in PIK3CA-mutated, hormone receptor-positive, HER2-negative advanced or metastatic breast cancer (GO39374): An open-label, multicentre, dose-escalation and dose-expansion phase 1/1b study
Inavolisib plus ET demonstrated a manageable safety profile and encouraging preliminary anti-tumour activity in patients with PIK3CA-mutated, HR-positive, HER2-negative LA/mBC, including those in the post-CDK4/6i setting.
Authors
- Erika Hamilton (ORCID: https://orcid.org/0000-0002-1911-0336)
- Sravanthi Cheeti (ORCID: https://orcid.org/0000-0003-2933-6328)
- P. Kellie Turner (ORCID: https://orcid.org/0000-0002-8703-5438)
- Ian E. Krop (ORCID: https://orcid.org/0000-0002-6380-5944)
- Jennifer L. Schutzman (ORCID: https://orcid.org/0009-0007-3697-5300)
- Anwesha Dey (ORCID: https://orcid.org/0000-0001-5688-5942)
- Philippe Lucien Bedard (ORCID: https://orcid.org/0000-0002-6771-2999)
- Komal L. Jhaveri (ORCID: https://orcid.org/0000-0003-0472-1254)
- Valentina Gambardella (ORCID: https://orcid.org/0000-0001-6081-8830)
- Mafalda Oliveira (ORCID: https://orcid.org/0000-0001-9152-8799)
- Stephanie Hilz (ORCID: https://orcid.org/0000-0002-6995-6719)
- Melissa Accordino (ORCID: https://orcid.org/0000-0002-4156-7279)
- Noopur Shankar (ORCID: https://orcid.org/0009-0005-5698-6782)
- Ubong Peters (ORCID: https://orcid.org/0000-0002-2491-9519)
- Stephanie Royer‐Joo (ORCID: https://orcid.org/0000-0003-4205-9927)
- Cristina Saura (ORCID: https://orcid.org/0000-0001-8296-5065)
- Kyung Song (ORCID: https://orcid.org/0000-0002-9761-8733)
- Dejan Juric (ORCID: https://orcid.org/0000-0003-2983-7704)
- Katherine E. Hutchinson (ORCID: https://orcid.org/0000-0002-4660-3523)
- Andrés Cervantes (ORCID: https://orcid.org/0000-0003-3806-3691)
- Yanling Jin (ORCID: https://orcid.org/0009-0004-6546-5201)
- Andrea Varga (ORCID: https://orcid.org/0000-0002-8673-1482)
- Junko Aimi (ORCID: https://orcid.org/0009-0006-8613-7770)
- Patrick Schmid
- Prof Antoine Italiano
- Prof Kevin Kalinsky
Institutions
- Memorial Sloan Kettering Cancer Center (US)
- Institute of Cancer Research (GB)
- Emory University (US)
- Université de Bordeaux (FR)
- Universitat de València (ES)
- Queen Mary University of London (GB)
- Cornell University (US)
- Columbia University Irving Medical Center (US)
- Institut Gustave Roussy (FR)
- Princess Margaret Cancer Centre (CA)
- Yale Cancer Center (US)
- Massachusetts General Hospital (US)
- Roche (Canada) (CA)
- Sarah Cannon (US)
- Dana-Farber Cancer Institute (US)
- Royal Marsden Hospital (GB)
- Vall d'Hebron Hospital Universitari (ES)
- Institut Bergonié (FR)
- INCLIVA Health Research Institute (ES)
- Vall d'Hebron Institute of Oncology (ES)
Publication Details
- Journal
- European Journal of Cancer
- Published
- 2025-04-01
- DOI
- https://doi.org/10.1016/j.ejca.2025.115397
- Citations
- 7
- Primary Topic
- Advanced Breast Cancer Therapies
- Type
- article
- Field-Weighted Citation Impact
- 10.63